Ali Moussa to Survival Analysis
This is a "connection" page, showing publications Ali Moussa has written about Survival Analysis.
Connection Strength
0.033
-
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440.
Score: 0.033